Total transaction consideration:. Transaction subject to customary closing conditions and regulatory approvals board and AppTec shareholder approval. Valuation and financial impact.
Source: WuXi management estimates. Strategic Rationale for Planned Acquisition. Focus on building capabilities and capacity to drive future growth.
Organic growth complemented by selective strategic partnerships and acquisitions. Obtain capabilities and expertise in biologics testing and manufacturing.
Gain significant US operational footprint. AppTec Overview. An industry leader in biological testing and manufacturing services for the biologics and medical device industries. Established relationships with many leading medical devices, pharma and biotech companies. Paul and Atlanta. Experienced and proven management team. Service offerings.
Development Testing Manufacturing. Toxicology Monoclonal antibodies. Scale up Histopathology. Paul Philadelphia Atlanta. Comprehensive microbiology testing. Biologics-based medical device manufacturing. Cellular therapeutics. NOTE: We do not provide fare estimates or taxi quotes over email.
TaxiFareFinder is not associated with taxi companies or limo services. The fares are based on the published rates provided by the respective municipalities for travel within city limits. Construction, traffic, weather, recent rate increases and other unforeseeable events may impact or alter the fare. TaxiFareFinder does not guarantee the accuracy of the information provided. All warranties are hereby disclaimed and TaxiFareFinder denies any and all liability for a user's reliance on the information provided which is provided free of charge and for planning purposes only.
Passcode: About WuXi PharmaTech. These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.
Our preliminary Q3 operating results may change as a result of final management review, review by outside auditors, finalization of share-based compensation expenses and closing adjustments for the quarter. We may be unable to successfully expand our capabilities to meet client needs. In addition other factors that could cause our actual results to differ from what we currently anticipate include our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependency upon the continued service of our senior management and key scientific personnel and ability to retain our existing customers or expand our customer base.
Our preliminary results of operations for the third quarter are not necessarily indicative of our operating results for any future periods.
Any projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward- looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.